176 related articles for article (PubMed ID: 35181565)
1. UNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies.
Tan DJH; Lim WH; Yong JN; Ng CH; Muthiah MD; Tan EX; Xiao J; Lim SY; Pin Tang AS; Pan XH; Kabir T; Bonney GK; Sundar R; Syn N; Kim BK; Dan YY; Noureddin M; Loomba R; Huang DQ
Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1475-1484. PubMed ID: 35181565
[TBL] [Abstract][Full Text] [Related]
2. National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time.
Mehta N; Dodge JL; Grab JD; Yao FY
Hepatology; 2020 Mar; 71(3):943-954. PubMed ID: 31344273
[TBL] [Abstract][Full Text] [Related]
3. Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria.
Kardashian A; Florman SS; Haydel B; Ruiz RM; Klintmalm GB; Lee DD; Taner CB; Aucejo F; Tevar AD; Humar A; Verna EC; Halazun KJ; Chapman WC; Vachharajani N; Hoteit M; Levine MH; Nguyen MH; Melcher ML; Langnas AN; Carney CA; Mobley C; Ghobrial M; Amundsen B; Markmann JF; Sudan DL; Jones CM; Berumen J; Hemming AW; Hong JC; Kim J; Zimmerman MA; Nydam TL; Rana A; Kueht ML; Fishbein TM; Markovic D; Busuttil RW; Agopian VG
Hepatology; 2020 Dec; 72(6):2014-2028. PubMed ID: 32124453
[TBL] [Abstract][Full Text] [Related]
4. National Experience on Waitlist Outcomes for Down-Staging of Hepatocellular Carcinoma: High Dropout Rate in All-Comers.
Huang AC; Dodge JL; Yao FY; Mehta N
Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1581-1589. PubMed ID: 36038129
[TBL] [Abstract][Full Text] [Related]
5. Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium.
Mehta N; Frenette C; Tabrizian P; Hoteit M; Guy J; Parikh N; Ghaziani TT; Dhanasekaran R; Dodge JL; Natarajan B; Holzner ML; Frankul L; Chan W; Fobar A; Florman S; Yao FY
Gastroenterology; 2021 Nov; 161(5):1502-1512. PubMed ID: 34331914
[TBL] [Abstract][Full Text] [Related]
6. Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol.
Sinha J; Mehta N; Dodge JL; Poltavskiy E; Roberts J; Yao F
Hepatology; 2019 Oct; 70(4):1185-1196. PubMed ID: 30779440
[TBL] [Abstract][Full Text] [Related]
7. Risk Factors and Center-Level Variation in Hepatocellular Carcinoma Under-Staging for Liver Transplantation.
Mahmud N; Hoteit MA; Goldberg DS
Liver Transpl; 2020 Aug; 26(8):977-988. PubMed ID: 32363720
[TBL] [Abstract][Full Text] [Related]
8. International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria.
Degroote H; Piñero F; Costentin C; Notarpaolo A; Boin IF; Boudjema K; Baccaro C; Chagas AL; Bachellier P; Ettorre GM; Poniachik J; Muscari F; Di Benedetto F; Duque SH; Salame E; Cillo U; Gadano A; Vanlemmens C; Fagiuoli S; Rubinstein F; Burra P; Cherqui D; Silva M; Van Vlierberghe H; Duvoux C;
JHEP Rep; 2021 Oct; 3(5):100331. PubMed ID: 34485882
[TBL] [Abstract][Full Text] [Related]
9. Downstaging hepatocellular carcinoma: A systematic review and pooled analysis.
Parikh ND; Waljee AK; Singal AG
Liver Transpl; 2015 Sep; 21(9):1142-52. PubMed ID: 25981135
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
[TBL] [Abstract][Full Text] [Related]
11. Downstaging hepatocellular carcinoma before liver transplantation: A multicenter analysis of the "all-comers" protocol in the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) consortium.
Natarajan B; Tabrizian P; Hoteit M; Frenette C; Parikh N; Ghaziani T; Dhanasekaran R; Guy J; Shui A; Florman S; Yao FY; Mehta N
Am J Transplant; 2023 Nov; 23(11):1771-1780. PubMed ID: 37532179
[TBL] [Abstract][Full Text] [Related]
12. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database.
Mehta N; Dodge JL; Roberts JP; Yao FY
Am J Transplant; 2018 May; 18(5):1206-1213. PubMed ID: 29068145
[TBL] [Abstract][Full Text] [Related]
13. A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence After Liver Transplantation: The Recurrent Hepatocellular Carcinoma-Initial, Maximum, Last Classification.
Vutien P; Dodge J; Bambha KM; Nordstrom EM; Gralla J; Campbell K; Levek C; Nydam T; Fix O; Ioannou G; Biggins SW
Liver Transpl; 2019 Apr; 25(4):559-570. PubMed ID: 30706653
[TBL] [Abstract][Full Text] [Related]
14. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study.
Mehta N; Guy J; Frenette CT; Dodge JL; Osorio RW; Minteer WB; Roberts JP; Yao FY
Clin Gastroenterol Hepatol; 2018 Jun; 16(6):955-964. PubMed ID: 29175528
[TBL] [Abstract][Full Text] [Related]
15. Radiological-histopathological discordance in patients transplanted for HCC and its impact on post-transplant outcomes.
Mohamed IB; Ismail MS; El Sabagh A; Afifi Abdelwahab AM; Polychronopoulou E; Kuo YF; Hassan M; Goss JA; Kanwal F; Jalal PK
Cancer Med; 2023 Jul; 12(14):15011-15025. PubMed ID: 37326440
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of loco-regional therapy for down-staging of hepatocellular carcinoma prior to liver transplantation.
Shi XJ; Jin X; Wang MQ; Wei LX; Ye HY; Liang YR; Luo Y; Dong JH
Hepatobiliary Pancreat Dis Int; 2011 Apr; 10(2):143-50. PubMed ID: 21459720
[TBL] [Abstract][Full Text] [Related]
18. Recurrent hepatocellular carcinoma after liver transplant: identifying the high-risk patient.
Nissen NN; Menon V; Bresee C; Tran TT; Annamalai A; Poordad F; Fair JH; Klein AS; Boland B; Colquhoun SD
HPB (Oxford); 2011 Sep; 13(9):626-32. PubMed ID: 21843263
[TBL] [Abstract][Full Text] [Related]
19. Transplantation vs resection for hepatocellular carcinoma with compensated liver function after downstaging therapy.
Lei JY; Yan LN; Wang WT
World J Gastroenterol; 2013 Jul; 19(27):4400-8. PubMed ID: 23885153
[TBL] [Abstract][Full Text] [Related]
20. Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma.
Meischl T; Rasoul-Rockenschaub S; Győri G; Scheiner B; Trauner M; Soliman T; Berlakovich G; Pinter M
United European Gastroenterol J; 2021 Mar; 9(2):209-219. PubMed ID: 32741316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
